82 related articles for article (PubMed ID: 16549901)
21. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
22. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy.
Stine KC; Saylors RL; Saccente CS; Becton DL
Clin Appl Thromb Hemost; 2007 Apr; 13(2):161-5. PubMed ID: 17456625
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
24. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
25. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparin in thrombotic disease in children and adolescents.
Punzalan RC; Hillery CA; Montgomery RR; Scott CA; Gill JC
J Pediatr Hematol Oncol; 2000; 22(2):137-42. PubMed ID: 10779027
[TBL] [Abstract][Full Text] [Related]
27. Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
Lang A; Kienitz C; Wetzel P; Rollnik JD
Clin Appl Thromb Hemost; 2011 Oct; 17(5):470-5. PubMed ID: 20547551
[TBL] [Abstract][Full Text] [Related]
28. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the use of low-molecular-weight heparin in neonates: a retrospective, single-center study.
Chander A; Nagel K; Wiernikowski J; Paes B; Chan AK;
Clin Appl Thromb Hemost; 2013 Sep; 19(5):488-93. PubMed ID: 23478571
[TBL] [Abstract][Full Text] [Related]
30. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
31. Out-patient treatment of acute deep vein thrombosis.
Mattiasson I; Berntorp E; Bornhov S; Lagerstedt C; Lethagen S; Persson J; Timberg I; Torstensson I
Int Angiol; 1998 Sep; 17(3):146-50. PubMed ID: 9821026
[TBL] [Abstract][Full Text] [Related]
32. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
33. Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study.
Bohnhoff JC; DiSilvio SA; Aneja RK; Shenk JR; Domnina YA; Brozanski BS; Good M
J Perinatol; 2017 Mar; 37(3):306-310. PubMed ID: 27906197
[TBL] [Abstract][Full Text] [Related]
34. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
35. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
36. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
37. Overview of enoxaparin in the treatment of deep vein thrombosis.
Deitcher SR
Am J Manag Care; 2000 Nov; 6(20 Suppl):S1026-33. PubMed ID: 11484302
[TBL] [Abstract][Full Text] [Related]
38. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
39. [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
Vorob'eva NM; Panchenko EP; Kirienko AI; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Andriiashkin VV; Leont'ev SG
Ter Arkh; 2009; 81(9):57-61. PubMed ID: 19827655
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]